Advanced search    

Search: authors:"Alicia Gutierrez-Valencia"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

The authors are indebted to the patients for their involvement in this study. Author Contributions Conceptualization: Alicia Gutierrez-Valencia, Juan Pasquau, Luis Fernando LoÂpez-CorteÂs. Data ... curation: Alicia Gutierrez-Valencia, Luis Fernando LoÂpez-CorteÂs. Formal analysis: Alicia Gutierrez-Valencia, Luis Fernando LoÂpez-CorteÂs. Funding acquisition: Alicia Gutierrez-Valencia, Luis Fernando

Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir

Background. Detrimental bidirectional pharmacokinetic interactions have been observed when telaprevir (TVR) and ritonavir (RTV)-boosted human immunodeficiency virus (HIV) protease inhibitors are coadministered in healthy volunteers. Our aim was to evaluate the role of RTV in the bidirectional TVR and atazanavir (ATV) interactions. Method. An open-label, sequential study was...

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

Background The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-α2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment. Methods Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-naïve HCV genotype 3 patients with HIV co-infection...